<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002001</url>
  </required_header>
  <id_info>
    <org_study_id>052B</org_study_id>
    <secondary_id>02</secondary_id>
    <nct_id>NCT00002001</nct_id>
  </id_info>
  <brief_title>The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease</brief_title>
  <official_title>The Antiviral Efficacy of Concurrent Zidovudine and 2',3'-Dideoxyinosine or 2',3'-Dideoxycytidine in Patients With Human Immunodeficiency Virus Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the virologic effect of combined administration of zidovudine and ddI or ddC. To&#xD;
      evaluate the immunologic effects of zidovudine and ddI or ddC. To evaluate combined&#xD;
      administration of zidovudine and ddI or ddC for clinical efficacy. To evaluate the safety and&#xD;
      the tolerance of the coadministration of zidovudine and ddI or ddC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zalcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Patients with PCP may be randomized to study medication after contacting the sponsor&#xD;
             and following a minimum 7-day course of therapy resulting in stabilization of their&#xD;
             disease. Patients with stabilized disease must have fever &lt; 39 C for at least 48&#xD;
             hours, p02 (on room air) &gt; or = 60 mm and an A/A gradient &lt; or = 30 mm.&#xD;
&#xD;
          -  Prophylaxis for PCP.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  HIV-1 seropositive by any federally licensed ELISA.&#xD;
&#xD;
          -  Willingness to give informed consent.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Any immediately life-threatening infection or medical condition present at time of&#xD;
             study entry.&#xD;
&#xD;
          -  Any active opportunistic infection requiring chronic therapy with any of the agents&#xD;
             listed in the exclusion concurrent medication section.&#xD;
&#xD;
          -  Neoplasms other than basal cell carcinoma or in situ carcinoma of the cervix.&#xD;
&#xD;
          -  Kaposi's sarcoma with visceral involvement or requiring systemic cytotoxic&#xD;
             chemotherapy.&#xD;
&#xD;
          -  AIDS dementia complex, &gt; or = Stage 2.&#xD;
&#xD;
          -  History of zidovudine induced toxicity.&#xD;
&#xD;
          -  Prior history of acute pancreatitis during the past two years or chronic pancreatitis.&#xD;
&#xD;
          -  Grade 2 neuropathy.&#xD;
&#xD;
          -  Intractable diarrhea.&#xD;
&#xD;
          -  History of seizures within the past six months or current requirement of&#xD;
             anticonvulsants.&#xD;
&#xD;
          -  Past or current heart disease.&#xD;
&#xD;
          -  Fever &gt; 39 C at entry.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Current requirement of anticonvulsants.&#xD;
&#xD;
          -  Excluded:&#xD;
&#xD;
          -  It is intended that patients developing new opportunistic infections during the course&#xD;
             of the study will continue study participation, unless required therapy is associated&#xD;
             with significant neurologic or hematologic toxicities, in which case the study&#xD;
             medication may be temporarily discontinued.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Chloramphenicol.&#xD;
&#xD;
          -  Cisplatinum.&#xD;
&#xD;
          -  Iodoquinol.&#xD;
&#xD;
          -  Systemic Pentamidine.&#xD;
&#xD;
          -  Disulfiram.&#xD;
&#xD;
          -  Ethionamide.&#xD;
&#xD;
          -  Glutethimide.&#xD;
&#xD;
          -  Gold.&#xD;
&#xD;
          -  Hydralazine.&#xD;
&#xD;
          -  Metronidazole.&#xD;
&#xD;
          -  Sodium Cyanate.&#xD;
&#xD;
          -  Thalidomide.&#xD;
&#xD;
          -  Vincristine.&#xD;
&#xD;
          -  Allopurinol.&#xD;
&#xD;
          -  Probenecid.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy. (with the exception of electron beam therapy to an area of &lt;&#xD;
             100cm/m2.)&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Any immediately life-threatening infection or medical condition present at time of&#xD;
             study entry.&#xD;
&#xD;
          -  Any active opportunistic infection requiring chronic therapy with any of the agents&#xD;
             listed in the exclusion concurrent medication section.&#xD;
&#xD;
          -  Active alcohol or drug abuse, sufficient in the investigator's opinion to prevent&#xD;
             compliance with study therapy.&#xD;
&#xD;
          -  Neoplasms other than basal cell carcinoma or in situ carcinoma of the cervix.&#xD;
&#xD;
          -  Kaposi's syndrome with visceral involvement or requiring systemic cytotoxic&#xD;
             chemotherapy.&#xD;
&#xD;
          -  AIDS dementia complex, &gt; or = Stage 2.&#xD;
&#xD;
          -  History of zidovudine induced toxicity.&#xD;
&#xD;
          -  Any experimental therapy within 30 days.&#xD;
&#xD;
          -  Prior history of acute pancreatitis during the past two years or chronic pancreatitis.&#xD;
&#xD;
          -  Grade 2 neuropathy.&#xD;
&#xD;
          -  Intractable diarrhea.&#xD;
&#xD;
          -  History of seizures within the past six months or current requirement of&#xD;
             anticonvulsants.&#xD;
&#xD;
          -  History of past or current heart disease.&#xD;
&#xD;
          -  Fever &gt; 39 C at entry.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any anti-HIV therapy (other than zidovudine), biologic response modifiers, or&#xD;
             pharmacologic doses of corticosteroids within eight weeks of entry (except for the&#xD;
             management of severe PCP, in which case duration is not to exceed 21 days).&#xD;
&#xD;
          -  Zidovudine therapy for greater than four weeks or prior discontinuation due to drug&#xD;
             toxicity.&#xD;
&#xD;
          -  Prior therapy with ddI, ddC, D4T, or interferon.&#xD;
&#xD;
          -  Any experimental therapy within 30 days.&#xD;
&#xD;
          -  Therapy within 30 days with neurotoxic drugs.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy within two weeks of entry or likely to require radiation therapy&#xD;
             (with the exception of electron beam therapy to an area of &lt; 100cm/m2).&#xD;
&#xD;
        Active alcohol or drug abuse, sufficient in the investigator's opinion, to prevent&#xD;
        compliance with study therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ of Colorado Health Sciences Ctr</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Univ Med Ctr / Main Hosp 4</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt School of Medicine</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent's Hosp Med Centre</name>
      <address>
        <city>Darlinghurst</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan Veterans Administration Med Ctr</name>
      <address>
        <city>San Juan</city>
        <zip>009275800</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JM, Pennington KN, St Clair MH. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group. J Virol. 1996 Sep;70(9):5922-9. doi: 10.1128/JVI.70.9.5922-5929.1996.</citation>
    <PMID>8709213</PMID>
  </reference>
  <verification_date>September 1991</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Zalcitabine</keyword>
  <keyword>Didanosine</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Zalcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

